Nebivololo efficacy on pressure control and endothelial dysfunction in hypertensive post-menopausal women
Poster
Data di Pubblicazione:
2010
Citazione:
Nebivololo efficacy on pressure control and endothelial dysfunction in hypertensive post-menopausal women / M. Vicenzi, M. Guazzi. - In: JOURNAL OF HYPERTENSION. - ISSN 0263-6352. - 28:e suppl. A(2010 Jun), pp. e120-e120. ((Intervento presentato al 28. convegno European meeting on hypertension tenutosi a Oslo nel 2010 [10.1097/01.hjh.0000378558.47033.17].
Abstract:
Introduction: Arterial hypertension and endothelial dysfunction are closely
related factors in determining a higher cardiovascular risk in hypertensive
postmenopausal women. The nebivolol is a selective beta1-blocker with additional peripheral vasodilating properties related to an increase in nitricoxide (NO) bioavailability.
Aim of the Study: This study aims at testing the efficacy of endothelial dependent
effect of nebivolol in hypertensive postmenopausal women by evaluating (i) its effect on the physical performance and (ii) its ability to control the systolic arterial pressure (SAP) during maximal exertional test.
Materials and Methods: 13 hypertensive postmenopausal women (mean age:
53.2 1.64 years), who were already under treatment, underwent a brachial artery flow-mediated dilation (FMD) and cardiopulmonary exercise testing to determine peak oxigen consumption (VO2) before (T0) and after (T1) a treatment period with nebivolol (mean duration: 76.8 22.6 days; daily dose:
4.5 1.12 mg). The standard treatment was suspended between T0 and T1.
Results: The nebivolol did not differ from standard treatments as far as blood
pressure control is concerned. Nebivolol also improved the FMD (p<.05;
fig. 1) and determined a significant increase in VO2 peak consumption during
exercise (delta VO2 precent: 8.2 4.55%, p<0.02) without comprising
systolic pressure control.
Conclusion: Nebivolol determines (i) a significant improvement of the
endothelial function while keeping blood pressure under control; (ii) an
increased exertional performance. These results suggest that nebivolol shuld
be preferentially used as a main anti-hypertensive drug in postmenopausal
women.
(Poster Session 06: Endothelium)
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
M. Vicenzi, M. Guazzi
Link alla scheda completa: